Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Lessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIA.

Phillips LM, Hachamovitch R, Berman DS, Iskandrian AE, Min JK, Picard MH, Kwong RY, Friedrich MG, Scherrer-Crosbie M, Hayes SW, Sharir T, Gosselin G, Mazzanti M, Senior R, Beanlands R, Smanio P, Goyal A, Al-Mallah M, Reynolds H, Stone GW, Maron DJ, Shaw LJ.

J Nucl Cardiol. 2013 Dec;20(6):969-75. doi: 10.1007/s12350-013-9773-4. Review.

2.

Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials.

Fernandez SF, Boden WE.

Curr Atheroscler Rep. 2010 Nov;12(6):423-31. doi: 10.1007/s11883-010-0135-2. Review.

PMID:
20845088
3.

Impact of myocardial ischemia on myocardial revascularization in stable ischemic heart disease. Lessons from the COURAGE and FAME 2 trials.

Torosoff MT, Sidhu MS, Boden WE.

Herz. 2013 Jun;38(4):382-6. doi: 10.1007/s00059-013-3824-0.

PMID:
23695652
4.

Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise.

Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB Jr, Harrington RA, Maron DJ.

J Am Coll Cardiol. 2016 Jan 5;67(1):81-99. doi: 10.1016/j.jacc.2015.09.056. Epub 2015 Nov 23. Review.

5.

Challenges with Evidence-Based Management of Stable Ischemic Heart Disease.

Patel AV, Bangalore S.

Curr Cardiol Rep. 2017 Feb;19(2):11. doi: 10.1007/s11886-017-0820-7. Review.

PMID:
28185167
6.

Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial?

Cheng-Torres KA, Desai KP, Sidhu MS, Maron DJ, Boden WE.

Future Cardiol. 2016 Jan;12(1):35-44. doi: 10.2217/fca.15.57. Epub 2015 Dec 21.

PMID:
26696561
7.

Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia.

Gada H, Kirtane AJ, Kereiakes DJ, Bangalore S, Moses JW, Généreux P, Mehran R, Dangas GD, Leon MB, Stone GW.

Am J Cardiol. 2015 May 1;115(9):1194-9. doi: 10.1016/j.amjcard.2015.01.556. Epub 2015 Feb 12. Review.

PMID:
25759103
8.

The elusive role of myocardial perfusion imaging in stable ischemic heart disease: Is ISCHEMIA the answer?

Xie JX, Winchester DE, Phillips LM, Hachamovitch R, Berman DS, Blankstein R, Di Carli MF, Miller TD, Al-Mallah MH, Shaw LJ.

J Nucl Cardiol. 2017 Oct;24(5):1610-1618. doi: 10.1007/s12350-017-0963-3. Epub 2017 Jul 27.

PMID:
28752313
9.

How and when to decide on revascularization in stable ischemic heart disease.

Mecklai A, Bangalore S, Hochman J.

Curr Treat Options Cardiovasc Med. 2013 Feb;15(1):79-92. doi: 10.1007/s11936-012-0214-5.

PMID:
23143818
10.

Trend in percutaneous coronary intervention volume following the COURAGE and BARI-2D trials: insight from over 8.1 million percutaneous coronary interventions.

Bangalore S, Gupta N, Généreux P, Guo Y, Pancholy S, Feit F.

Int J Cardiol. 2015 Mar 15;183:6-10. doi: 10.1016/j.ijcard.2015.01.053. Epub 2015 Jan 27.

PMID:
25662046
11.

Effect of Percutaneous Coronary Intervention on Survival in Patients with Stable Ischemic Heart Disease.

Ujueta F, Weiss EN, Shah B, Sedlis SP.

Curr Cardiol Rep. 2017 Feb;19(2):17. doi: 10.1007/s11886-017-0821-6. Review.

PMID:
28213668
12.

Revascularization options in stable coronary artery disease: it is not how to revascularize, it is whether and when to revascularize.

Torosoff MT, Sidhu MS, Desai KP, Fein SA, Boden WE.

J Comp Eff Res. 2015 Sep;4(5):505-14. doi: 10.2217/cer.15.37. Epub 2015 Sep 21. Review.

PMID:
26387530
13.

Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(16):1-167. Epub 2005 Oct 1.

14.

[Ischemic cardiomyopathy: possibilities of surgical treatment].

Benetis R, Simukauskiene A, Jankauskiene L, Kavoliūniene A.

Medicina (Kaunas). 2007;43(11):909-17. Review. Lithuanian.

15.

Impact of ischemia and scar on therapeutic benefit of myocardial revascularization.

Hachamovitch R.

Herz. 2013 Jun;38(4):344-9. doi: 10.1007/s00059-013-3804-4.

PMID:
23625299
16.

Clinical implications of the BARI 2D and COURAGE trials: overview.

Brooks MM, Boden WE, Frye RL.

Coron Artery Dis. 2010 Nov;21(7):383-5. doi: 10.1097/MCA.0b013e32833d014a.

17.

Fractional flow reserve-guided coronary bypass surgery: should surgeons use it?

Ferguson TB Jr, Chen C, Buch AN.

Curr Opin Cardiol. 2013 Nov;28(6):654-60. doi: 10.1097/HCO.0b013e32836581a3. Review.

PMID:
24100651
18.

Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention.

Shaw LJ, Weintraub WS, Maron DJ, Hartigan PM, Hachamovitch R, Min JK, Dada M, Mancini GB, Hayes SW, O'Rourke RA, Spertus JA, Kostuk W, Gosselin G, Chaitman BR, Knudtson M, Friedman J, Slomka P, Germano G, Bates ER, Teo KK, Boden WE, Berman DS.

Am Heart J. 2012 Aug;164(2):243-50. doi: 10.1016/j.ahj.2012.05.018.

PMID:
22877811
19.

Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease.

Melikian N, De Bondt P, Tonino P, De Winter O, Wyffels E, Bartunek J, Heyndrickx GR, Fearon WF, Pijls NH, Wijns W, De Bruyne B.

JACC Cardiovasc Interv. 2010 Mar;3(3):307-14. doi: 10.1016/j.jcin.2009.12.010.

20.

Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials.

Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL.

JAMA Intern Med. 2014 Feb 1;174(2):232-40. doi: 10.1001/jamainternmed.2013.12855. Review.

PMID:
24296791

Supplemental Content

Support Center